Clinical Trials Directory

Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma

The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : PCI-32765

Phase: Phase 1


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Women and men ? 18 years of age. There is no experience with this drug in a pediatric population. - Body weight ? 40 kg. - Recurrent surface immunoglobulin positive B cell non-Hodgkin's lymphoma (NHL) according to WHO classification, including small lymphocytic lymphoma/ chronic lymphocytic leukemia (SLL/CLL) lymphoplasmacytic lymphoma, including Waldenström's Macroglobulinemia (WM), and pre-identified DLBCL ABC subtype oFor the DLBCL-ABC cohort, documented, activated B-cell subtype by either immunohistochemistry or tissue microarray analysis. - Measurable disease (for NHL, bidimensional disease ? 2 cm diameter in at least one dimension, for CLL ? 5000 leukemia cells/mm3, for WM presence of immunoglobulin M paraprotein with a minimum IgM level ? 1000 mg/dL and infiltration of bone marrow by lymphoplasmacytic cells), and pre-identified DLBCL ABC subtype by immunohistochemistry (IHC). - Have failed ? 1 previous treatment for lymphoma and no standard therapy is available. Patients with diffuse large B cell lymphoma must have failed, refused or be ineligible for autologous stem cell transplant. - ECOG performance status of ? 1. - Ability to swallow oral capsules without difficulty. - Willing and able to sign a written informed consent.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting

Footer Links: